New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
10:02 EDTAZN, EBAY, SMF, DLLR, CRFN, ROSE, EHTH, UAM, UNH, UPL, HBI, GNC, DVA, FFIVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AstraZeneca (AZN) upgraded to Neutral from Underweight at JPMorgan... DaVita (DVA) upgraded to Buy from Hold at Deutsche Bank... GNC Holdings (GNC) upgraded to Buy from Hold at Deutsche Bank... Hanesbrands (HBI) upgraded to Overweight from Equal Weight at Barclays... Qualcomm (QCOM) upgraded to Strong Buy from Outperform at Raymond James... Ultra Petroleum (UPL) upgraded to Buy from Hold at Brean Capital... UnitedHealth (UNH) upgraded to Strong Buy from Outperform at Raymond James... Universal American (UAM) upgraded to Market Perform from Underperform at Raymond James... eHealth (EHTH) upgraded to Buy from Neutral at Janney Capital... Rosetta Resources (ROSE) upgraded to Focus List from Sector Perform at Howard Weil... Qualcomm (QCOM) upgraded at Raymond James... Crescent Financial (CRFN) upgraded to Outperform from Market Perform at Raymond Jamesl... DFC Global (DLLR) upgraded to Buy from Neutral at Nomura... Salient MLP & Energy Infrastructure (SMF) upgraded to Buy from Hold at Stifel... eBay (EBAY) upgraded to Buy from Hold at Topeka... F5 Networks (FFIV) upgraded to Outperform from Neutral at RW Baird.
News For AZN;DVA;GNC;HBI;UPL;UNH;UAM;EHTH;ROSE;CRFN;DLLR;SMF;EBAY;FFIV From The Last 14 Days
Check below for free stories on AZN;DVA;GNC;HBI;UPL;UNH;UAM;EHTH;ROSE;CRFN;DLLR;SMF;EBAY;FFIV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 21, 2014
10:34 EDTEBAYeBay jumps after report says PayPal spin-off under consideration
Subscribe for More Information
10:14 EDTEBAYeBay jumps 2% to $54.55 after The Information report on PayPal spin
Subscribe for More Information
10:14 EDTROSEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:14 EDTEBAYeBay saying PayPal spin-off may come next year, The Information reports
eBay has been telling PayPal CEO candidates that it is considering spinning off the payments business as soon as next year, The Information reports, citing two people briefed on the conversations. Reference Link
09:54 EDTAZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
07:38 EDTROSERosetta Resources upgraded to Accumulate from Hold at KLR Group
KLR Group upgraded Rosetta Resources to Accumulate with a $59 price target citing solid Eagle Ford execution.
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTFFIVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:51 EDTGNCGNC purchase of shares by chairman a vote of confidence, says Sterne Agee
Subscribe for More Information
08:32 EDTFFIVF5 Networks upgraded at ISI Group
As noted earlier, ISI Group upgraded F5 Networks to Strong Buy from Buy. The firm thinks the company's positioning vis-a-vis NFN/SDN has improved, while its momentum from a number of growth drivers, including security, has increased. The firm is now more confident that the company's EPS could approach $7 in 2015. Target $135.
06:11 EDTEBAYeBay volatility at record low
Subscribe for More Information
August 19, 2014
21:06 EDTFFIVF5 Networks upgraded to Strong Buy from Buy at ISI Group
16:00 EDTEBAYOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
13:04 EDTEBAYPayPal taking up Braintree’s Venmo Touch technology, GigaOM says
Subscribe for More Information
11:05 EDTFFIVImperva seen as takeover candidate under new CEO
Subscribe for More Information
08:42 EDTFFIVImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
08:03 EDTHBICarter's has favorable risk/reward, says Goldman
Goldman said cotton prices are at a 5-year low and basic apparel companies Carter's (CRI) which is Buy rated, Gildan (GIL), and HanesBrands (HBI), both Neutral rated, are the most leveraged to the lower prices. The firm believes Carter's offers the best exposure to lower cotton prices and notes leadership in kids apparel and branding offering.
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
August 18, 2014
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use